You are here

Article info

Article menu
XML
Immunotherapy biomarkers
Original research
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma

Authors

  • Hua Bai State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jianchun Duan State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Chengcheng Li The Medical Department, Burning Rock Biotech, Guangzhou, China PubMed articlesGoogle scholar articles
  • Wenzhuan Xie The Medical Department, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Wenfeng Fang Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Yu Xu The Medical Department, Burning Rock Biotech, Guangzhou, China PubMed articlesGoogle scholar articles
  • Guoqiang Wang The Medical Department, Burning Rock Biotech, Guangzhou, China PubMed articlesGoogle scholar articles
  • Rui Wan State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jing Sun State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jiachen Xu State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Xin Wang State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Kailun Fei State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Zhengyi Zhao The Medical Department, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Shangli Cai The Medical Department, Burning Rock Biotech, Guangzhou, China PubMed articlesGoogle scholar articles
  • Li Zhang Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Jie Wang State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Zhijie Wang State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles

Citation

Bai H, Duan J, Li C, et al
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
Journal for ImmunoTherapy of Cancer 2020;8:e001315. doi: 10.1136/jitc-2020-001315
Online issue publication 
December 10, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.